VYGR Voyager Therapeutics, Inc.

Price Chart

Executive Summary

Cantor Fitzgerald initiated Voyager Therapeutics (VYGR) at Overweight with a $5.73 price target, representing 35% upside from the $4.24 close. The call is part of a three-firm cluster on January 10, 2025, including Citigroup and Leerink Partners, signaling coordinated bullish sentiment. Consensus is overwhelmingly bullish: 17 of 18 analysts rate Buy or Strong Buy, with only 1 Hold and zero Sell ratings. The mean price target is $14.89, implying 251% upside, though Cantor's $5.73 target is the lowest on the Street — a contrarian conservative stance. Cantor Fitzgerald's track record on VYGR is poor (0% accuracy on 2 calls, -28.2% avg return), and its overall accuracy is 49% on 1,996 calls, below the typical 55-60% benchmark. EPS estimates have been revised up in the last 7 and 30 days, a positive momentum signal. Insider selling persists: five executives sold shares totaling ~$156K in Feb-Apr 2026, including the CEO. Institutional activity is mixed: Bank of America trimmed 58.8% while Wells Fargo and Two Sigma added. The bottom line: Cantor's low-accuracy track record and below-consensus PT weaken this bullish initiation; the cluster of initiations is a modest positive, but insider selling and institutional trimming create headwinds.

Impact Score

Consensus & Targets

Consensus is 94% bullish: 8 Strong Buy, 9 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 18 analysts. The direction is heavily skewed to the upside, with only one hold rating. This is a near-unanimous bullish consensus, making Cantor's initiation in-line with the prevailing view.

Current price: $4.24. Mean target: $14.89 (implied upside +251%). Median: $12. High: $25 (HC Wainwright). Low: $8 (Wedbush). Cantor's $5.73 target is below the low end of the existing range, making it the most conservative on the Street. Implied upside to Cantor's target is +35%, far below the consensus mean upside.

Recent Analyst Activity

No upgrades or downgrades in the last 30 days. EPS estimates for the current fiscal year have been revised up: from -$1.77 to -$1.52 over 30 days, a positive revision trend. Revenue estimates also revised up. This is a modestly bullish momentum signal, supporting the initiation's direction.

Firm Track Record — Cantor Fitzgerald

Cantor Fitzgerald accuracy: 49% on 1996 calls | avg return: 5.3%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 4 firms with ≥5 scored calls.

Cantor Fitzgerald has a 49% accuracy rate on 1,996 calls, below the typical 55-60% benchmark. On VYGR specifically, they are 0-for-2 with a -28.2% average return, the worst among covering firms. Best performing firm on VYGR is Wedbush (50% on 4 calls, -0.7% avg return). Worst is Canaccord Genuity (0% on 2 calls, -25.5% avg return). Cantor's track record weakens the signal.

Earnings Estimates

Cross-Platform Signals

Insider selling is notable: five executives sold shares totaling ~$156K between Feb and Apr 2026, including CEO Sandrock Alfred ($54K) and CFO Jorgensen Nathan ($18K). These are routine sales, not cluster buys, so they carry weak negative signal per academic literature. Institutional activity is mixed: Bank of America trimmed 58.8% while Wells Fargo added 26.7% and Two Sigma added 58.3%. No congressional trades. Short interest data not available. The insider selling diverges from the bullish analyst signal, but per literature, sales alone are weak predictors.

Documents Analyzed

Report based on filing metadata.

US Market Status